Ombow, Thanks. >> the Data and Safety Monitoring Committee will be looking into the trial with results hopefully known in July <<
I think that will mainly focus on the safety aspects of the drug, not so much to assess efficacy, and they won't actually release 'results' at that time, but merely allow the trial to continue or not continue.
Sometimes they stop trials for toxicity reasons (very unlikely with Leronlimab), or when there is no sign of efficacy at all. In CYDY's case the Data and Safety Monitoring Committee will likely allow the trial to continue to completion, but we won't see any actual data/results made public.
An interim analysis is what we need. My concern would be if the mild/moderate trial disappoints next week, then investors don't want to wait too long for data from the severe trial. Since Leronlimab works at the cytokine storm level, the severe trial 'should' be the best chance to show good efficacy (theoretically).
News 
Market Data 
Discover 
